Trials that use: P-values
New to this method? Read the tutorial →
389 results
- D-CAREIndependent statistical analysis of the D-CARE phase 3 trial of denosumab as adjuvant treatment for women with high-risk early breast cancer, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, stratified log-rank…
- DAPA-CKDIndependent statistical analysis of the randomized phase 3 DAPA-CKD trial evaluating dapagliflozin versus placebo for renal and cardiovascular outcomes in patients with chronic kidney disease.
- DAPA-HFIndependent statistical analysis of the DAPA-HF phase 3 trial evaluating dapagliflozin in patients with chronic heart failure with reduced ejection fraction, including trial design, endpoints, Cox models, win ratio, rate ratio, results,…
- DAPA-MIIndependent statistical analysis of the DAPA-MI phase 3 trial of dapagliflozin versus placebo after acute myocardial infarction, including its hierarchical primary composite endpoint, win-ratio methodology, trial design, interpretation, and safety.
- DELIVERIndependent statistical analysis of the DELIVER phase 3 trial of dapagliflozin in heart failure with preserved ejection fraction, including its dual primary time-to-event endpoints, Cox models, recurrent-event analysis, KCCQ analysis, safety, and…
- DESTINY-Breast02Complete statistical analysis of DESTINY-Breast02, a randomized phase 3 trial of trastuzumab deruxtecan versus investigator's/physician's choice in previously treated HER2-positive, unresectable and/or metastatic breast cancer.
- DESTINY-Breast04Independent statistical analysis of DESTINY-Breast04, a randomized phase 3 trial of trastuzumab deruxtecan versus investigator's choice for HER2-low breast cancer. Includes the reported progression-free survival analysis, trial design, statistical methodology, interpretation, and…
- DESTINY-Breast06Independent statistical analysis of DESTINY-Breast06 (NCT04494425), a randomized phase 3 trial comparing trastuzumab deruxtecan with investigator's choice chemotherapy in HER2-low, hormone receptor-positive, advanced or metastatic breast cancer.
- DISCOVERIndependent statistical analysis of the DISCOVER phase 3 trial evaluating F/TAF versus F/TDF for HIV-1 pre-exposure prophylaxis, including non-inferiority testing, rate-ratio analysis, BMD, renal biomarkers, and statistical methodology.
- DUO-EIndependent statistical analysis of the phase 3 DUO-E trial evaluating durvalumab with or without olaparib as maintenance therapy after first-line treatment of advanced and recurrent endometrial cancer.
- E1912Independent statistical analysis of E1912 (NCT02048813), a randomized phase 3 trial comparing ibrutinib and rituximab with fludarabine, cyclophosphamide, and rituximab in untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
- E5103Independent statistical analysis of E5103 (NCT00433511), a randomized phase 3 trial evaluating doxorubicin, cyclophosphamide, and paclitaxel with or without bevacizumab in breast cancer.
- EINSTEIN-DVTIndependent statistical analysis of EINSTEIN-DVT, a randomized phase 3 trial of rivaroxaban versus enoxaparin followed by VKA in patients with venous thrombosis, including its non-inferiority analysis, Cox model, hazard ratio, confidence interval,…
- EINSTEIN-PEIndependent statistical analysis of EINSTEIN-PE, the randomized phase 3 trial of rivaroxaban versus enoxaparin followed by VKA in patients with acute symptomatic pulmonary embolism, including non-inferiority methodology, Cox analysis, hazard ratios, bleeding,…
- ELIXAIndependent statistical analysis of the ELIXA phase 3 trial of lixisenatide versus placebo in patients with acute coronary syndrome and type 2 diabetes, including its time-to-event endpoint, non-inferiority framework, hazard ratio, confidence…
- EMBER-3Independent statistical analysis of EMBER-3, a randomized phase 3 trial of imlunestrant, investigator's choice of endocrine therapy, and imlunestrant plus abemaciclib in participants with ER+, HER2- advanced breast cancer.
- EMBRACAIndependent statistical analysis of the EMBRACA phase 3 trial of talazoparib versus physician's choice treatment in advanced and/or metastatic breast cancer patients with BRCA mutation, including progression-free survival, response, overall survival, quality…
- EMERALDIndependent statistical analysis of the phase 3 EMERALD trial of elacestrant versus standard of care in ER+/HER2- advanced breast cancer, including progression-free survival, overall survival, stratified time-to-event methods, confidence intervals, and interpretation.
- EMILIAIndependent statistical analysis of the phase 3 EMILIA trial of trastuzumab emtansine versus lapatinib plus capecitabine in HER2-positive locally advanced or metastatic breast cancer, including time-to-event methods, response analyses, safety, and interpretation.
- EMPA-REG OUTCOMEComplete statistical analysis of EMPA-REG OUTCOME, the randomized phase 3 trial of empagliflozin in patients with type 2 diabetes mellitus, including its time-to-event endpoints, Cox proportional-hazards analyses, non-inferiority framework, cardiovascular outcomes, microvascular…
- EMPEROR-PreservedA detailed statistical analysis of EMPEROR-Preserved, the randomized phase 3 trial of 10 mg empagliflozin versus placebo in patients with heart failure, including time-to-event outcomes, Cox models, recurrent-event analysis, MMRM, and interpretation.
- EMPEROR-ReducedIndependent statistical analysis of EMPEROR-Reduced, a randomized phase 3 trial of empagliflozin versus placebo in chronic heart failure with reduced ejection fraction. Includes the registered time-to-event endpoint, Cox and mixed-effects analyses, reported…
- EMPULSEIndependent statistical analysis of the EMPULSE phase 3 trial of empagliflozin in patients hospitalized for acute heart failure, including the primary win-ratio endpoint, secondary analyses, statistical methodology, safety, and interpretation.
- ENDEAVORIndependent statistical analysis of the ENDEAVOR phase 3 trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone in relapsed multiple myeloma, including progression-free survival, overall survival, response, safety, and statistical methodology.
- ENESTndIndependent statistical analysis of ENESTnd (NCT00471497), a randomized phase 3 study comparing nilotinib with imatinib in adults with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.
- ENGAGEIndependent statistical analysis of the ENGAGE phase 3 trial of aducanumab in early Alzheimer's disease, including randomized trial design, CDR-SB and cognitive endpoints, MMRM methodology, confidence intervals, p-values, and safety.
- ENGAGE AF-TIMI 48Independent statistical analysis of ENGAGE AF-TIMI 48, evaluating edoxaban versus warfarin for stroke and systemic embolic events in patients with atrial fibrillation.
- ENVISAGE-TAVI AFComplete statistical analysis of ENVISAGE-TAVI AF, the randomized phase 3 trial comparing an edoxaban-based regimen with a vitamin K antagonist-based regimen in patients with atrial fibrillation after catheter-based heart valve replacement.
- EORTC 18071Independent statistical analysis of EORTC 18071, a randomized phase 3 trial of ipilimumab versus placebo after complete resection of high-risk stage III melanoma, including recurrence-free survival, distant metastasis-free survival, overall survival, and…
- EPIC-HRIndependent statistical analysis of the EPIC-HR randomized phase 2/3 trial of PF-07321332/ritonavir versus placebo in nonhospitalized high-risk adults with COVID-19, including endpoint definitions, statistical methods, reported results, safety, and interpretation.
- EUROMAXComplete statistical analysis of the EUROMAX phase 3 trial of bivalirudin versus standard-of-care heparins with optional GPI in acute coronary syndrome, including trial design, the primary binary endpoint, risk ratio, confidence interval,…
- EV-301Independent statistical analysis of EV-301, evaluating enfortumab vedotin versus chemotherapy in previously treated locally advanced or metastatic urothelial cancer, including overall survival, progression-free survival, response endpoints, methodology, and interpretation.
- EV-302Independent statistical analysis of EV-302, the randomized phase 3 trial of enfortumab vedotin plus pembrolizumab versus standard of care in untreated locally advanced or metastatic urothelial cancer.
- EVOKE-01Independent statistical analysis of EVOKE-01, a randomized phase 3 trial comparing sacituzumab govitecan with docetaxel in participants with advanced or metastatic non-small cell lung cancer, including overall survival, progression-free survival, response, patient-reported…
- EVOLVE-1Independent statistical analysis of the phase 3 EVOLVE-1 trial of galcanezumab for the prevention of episodic migraine, including randomized design, longitudinal mixed-effects analysis, odds ratios, Fisher exact testing, efficacy results, safety, and…
- EVOLVE-2Independent statistical analysis of the phase 3 EVOLVE-2 trial of galcanezumab for the prevention of episodic migraine, including trial design, registered endpoints, mixed-effects analyses, confidence intervals, secondary outcomes, safety information, and statistical…
- EXPEDITION 3Independent statistical analysis of EXPEDITION 3 (NCT01900665), a randomized phase 3 trial comparing solanezumab with placebo in participants with mild Alzheimer's disease, including the registered ADAS-Cog14 endpoint, mixed-effects analysis, confidence interval, p-value,…
- EXSCELA detailed independent statistical analysis of EXSCEL, the phase 3 trial of exenatide once weekly versus placebo in patients with type 2 diabetes mellitus, including its randomized design, time-to-event endpoints, Cox models,…
- ExteNETIndependent statistical analysis of the phase 3 ExteNET trial of neratinib after adjuvant trastuzumab in women with early stage breast cancer, including randomized design, time-to-event endpoints, hazard ratios, confidence intervals, survival methodology,…
- FEM-PrEPIndependent statistical analysis of FEM-PrEP, a randomized phase 3 trial evaluating Truvada versus placebo for preventing HIV acquisition in women, including its time-to-event analysis, safety endpoints, secondary outcomes, and statistical interpretation.
- FIDELIO-DKDAn independent statistical analysis of FIDELIO-DKD, the randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and diabetic kidney disease. Includes the primary renal composite, cardiovascular…
- FIGARO-DKDIndependent statistical analysis of FIGARO-DKD, a randomized phase 3 trial of finerenone versus placebo in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease.
- FINEARTS-HFIndependent statistical analysis of FINEARTS-HF, the randomized phase 3 trial evaluating finerenone versus placebo in participants with heart failure and left ventricular ejection fraction greater than or equal to 40%.
- FIRSTANAIndependent statistical analysis of the randomized phase 3 FIRSTANA trial of cabazitaxel versus docetaxel, both with prednisone, in patients with metastatic castration-resistant prostate cancer.
- FLAMEIndependent statistical analysis of the FLAME phase 3 trial of QVA149 versus LABA/ICS in COPD, including exacerbation rates, time-to-event analyses, non-inferiority methodology, safety, and statistical interpretation.
- FLAMINGOComplete statistical analysis of the FLAMINGO phase 3 trial comparing dolutegravir with darunavir/ritonavir, each combined with dual NRTIs in ART-naive participants with HIV-1 infection.
- FLAURAComplete statistical analysis of the phase 3 FLAURA trial of osimertinib versus standard-of-care EGFR-TKI therapy in locally advanced or metastatic EGFR sensitising mutation-positive non-small cell lung cancer.
- FLAURA2Independent statistical analysis of FLAURA2, the randomized phase 3 trial of osimertinib with chemotherapy versus osimertinib alone in first-line treatment of EGFR-mutated non-small cell lung cancer. Includes trial design, endpoints, survival analyses,…
- FLOWIndependent statistical analysis of the FLOW phase 3 trial of semaglutide versus placebo in people with type 2 diabetes and chronic kidney disease, including trial design, the composite renal endpoint, Cox proportional-hazards…
- FOURIERIndependent statistical analysis of the FOURIER phase 3 trial of evolocumab versus placebo in subjects with elevated cardiovascular risk and dyslipidemia, including time-to-event endpoints, hazard ratios, stratified log-rank testing, multiplicity, and interpretation.